rethinkPeptides Search
Menu
Study breakdown

Antimicrobial Peptides from Fish Show Promising Anticancer Activity in Lab Studies

evidence
The takeaway

A review of 15 studies finds that antimicrobial peptides derived from fish kill cancer cells through multiple mechanisms including oxidative stress and mitochondrial damage, while sparing normal cells.

15 studies, multiple mechanisms

Fish AMPs kill cancer cells through at least three pathways — ROS generation, mitochondrial dysfunction, and DNA damage — with selective cytotoxicity for cancer over normal cells

What the researchers found

Across 15 studies published between 2020 and 2024, fish-derived antimicrobial peptides (AMPs) demonstrated broad-spectrum anticancer activity against diverse cancer cell lines. The primary killing mechanisms were apoptosis and necrosis triggered through reactive oxygen species (ROS) generation, mitochondrial dysfunction, and DNA damage. Notably, these peptides showed selective cytotoxicity — preferentially killing cancer cells while being less toxic to normal cells. Some also exhibited antiangiogenic properties (blocking tumor blood vessel formation).

Why it matters

Cancer treatment needs new drug classes, especially those that can selectively target tumor cells. Fish-derived AMPs offer a promising direction because they kill cancer cells through multiple mechanisms simultaneously, making resistance harder to develop. Their selectivity for cancer cells over normal cells is particularly appealing, as conventional chemotherapy's lack of selectivity causes severe side effects.

The numbers in context

15 studies reviewed (2020–2024) · Multiple cancer cell lines tested · Mechanisms: ROS generation + mitochondrial dysfunction + DNA damage · Selective cytotoxicity demonstrated

How the study worked

Systematic mini-review of studies published between 2020 and 2024, sourced from Google Scholar, Scopus, BioMed Central, and ScienceDirect. Fifteen relevant research papers were identified and analyzed for evidence of fish-derived AMP anticancer activity, mechanisms of action, and therapeutic potential.

What this study cannot tell us

All evidence reviewed is from in vitro (cell culture) studies only — no animal models or human clinical trials are included. In vitro anticancer activity often fails to translate to in vivo efficacy due to peptide instability, poor bioavailability, and immune clearance. The review only covered 15 papers from a 4-year window, which may not capture the full scope of the field.

How to read the evidence

This is a mini-review of 15 in vitro studies. No animal or human data is included. The evidence shows consistent anticancer activity across multiple cell lines and studies, but in vitro results frequently fail to translate to clinical efficacy.

When this study was published

Published in 2026, this is a very recent review covering studies from 2020–2024. It represents the current state of a rapidly emerging field.

The bigger picture

The ocean is increasingly recognized as a rich source of bioactive peptides. Fish AMPs join a growing list of marine-derived peptide candidates for cancer therapy, alongside peptides from sea cucumbers, cone snails, and marine sponges. The dual antimicrobial-anticancer activity of these peptides makes evolutionary sense — both bacteria and cancer cells have distinct membrane properties that cationic peptides can exploit. As peptide engineering and delivery technologies improve, marine-derived AMPs could become a new class of cancer therapeutics.

Questions still open

  • Can fish-derived AMPs be stabilized and delivered effectively enough to work as cancer drugs in living organisms?
  • Which specific fish species produce the most potent anticancer AMPs, and can these be produced synthetically at scale?
  • Do these peptides work synergistically with existing chemotherapy drugs to enhance cancer cell killing?

Common questions

How do fish antimicrobial peptides kill cancer cells?
They use multiple mechanisms simultaneously: generating reactive oxygen species (toxic oxygen molecules) inside cancer cells, disrupting mitochondria (the cell's power plants), and damaging DNA. This multi-pronged attack triggers the cancer cell to self-destruct through apoptosis or necrosis. The peptides preferentially target cancer cells because cancer cell membranes have different properties than normal cells.
Could fish peptides ever become cancer drugs?
Potentially, but there's a long road ahead. All current evidence is from cells in lab dishes. The peptides would need to be stabilized against degradation, formulated for effective delivery to tumors, and tested in animals before human trials. The review notes that synthetic optimization and advanced delivery systems are required for clinical development.

Read the original research

Fish-Derived Antimicrobial Peptides (AMPs) as Anticancer Agents: A Mini-Review of In Vitro Evidence.

Anti-cancer agents in medicinal chemistry

Citation

Mohd Noordin, Muhammad Akram; Najm, Ahmed Abdulkareem; Dyari, Herryawan Ryadi Eziwar; Law, Douglas; Fazry, Shazrul. (2026). Fish-Derived Antimicrobial Peptides (AMPs) as Anticancer Agents: A Mini-Review of In Vitro Evidence.. Anti-cancer agents in medicinal chemistry. https://doi.org/10.2174/0118715206411478251125091213